Sign in

Cystic fibrosis: trials that stopped early

Trials on Cystic fibrosis that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

21 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

    Reason given in the registry

    “Sponsor's Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Oct 2026.

    Ended
    Aug 2026
    Phase
    Phase 1
    Run by
    Genentech, Inc.
    Registry record
    NCT06603246
  2. Suspended

    A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

    Reason given in the registry

    “The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2026.

    Phase
    Phase 2
    Run by
    Sanofi
    Registry record
    NCT07547436
  3. Withdrawn

    Real World Environmental Exposure Study With Healthy and Cystic Fibrosis Subjects

    Reason given in the registry

    “Significant difficulties in recruiting participants, particularly in the 'cystic fibrosis' group.The constraints placed on participants, in particular the requirement to walk for ten days (5 days in an urban area and 5 days in a green area)”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jun 2026.

    Run by
    Centre Hospitalier Intercommunal Creteil
    Registry record
    NCT06339450
  4. Terminated

    MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis

    Reason given in the registry

    “Target number of inclusion not reached”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jun 2026.

    Ended
    Mar 2025
    Run by
    University Hospital, Bordeaux
    Registry record
    NCT03357562
  5. Withdrawn

    Effects of AD on VI in Patients With CF

    Reason given in the registry

    “No recruitement, no grant to support this study”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Apr 2026.

    Ended
    Dec 2025
    Run by
    Cliniques universitaires Saint-Luc- Université Catholique de Louvain
    Registry record
    NCT03655249
  6. Terminated

    Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.

    Reason given in the registry

    “The pace of patient enrollment was significantly affected by the COVID-19 pandemic. Since this is an epidemiological study that does not require a specific number of patients to meet the primary objective, the enrollment period was not extended.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Mar 2026.

    Ended
    Jun 2024
    Run by
    University Hospital, Brest
    Registry record
    NCT03312075
  7. Terminated

    Diagnosis and Treatment of Patients With Cystic Fibrosis

    Reason given in the registry

    “PI left NIH”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Feb 2026.

    Ended
    Jan 2026
    Run by
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Registry record
    NCT00001223
  8. Suspended

    Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

    Reason given in the registry

    “Suspended for analysis and to consider further enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Jan 2026.

    Run by
    University of Pittsburgh
    Registry record
    NCT04306939
  9. Terminated

    Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease)

    Reason given in the registry

    “Recruitment issue”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Nov 2025.

    Ended
    Aug 2025
    Run by
    Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
    Registry record
    NCT06399094
  10. Terminated

    Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

    Reason given in the registry

    “Enrolment period completed and sufficient number of enrolments to achieve study objectives”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Sept 2025.

    Ended
    Feb 2025
    Run by
    University Hospital, Montpellier
    Registry record
    NCT05100823
  11. Terminated

    Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

    Reason given in the registry

    “Due to the decision to stop recruitment early, enrolment into the MAHALE trial was terminated in August 2022; 139 patients were screened and 100 randomised to IP.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Jul 2025.

    Ended
    Apr 2024
    Phase
    Phase 3
    Run by
    AstraZeneca
    Registry record
    NCT05006573
  12. Withdrawn

    Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

    Reason given in the registry

    “new drug formulation by the manufacturer”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Jun 2025.

    Ended
    Sept 2025
    Phase
    Phase 2/3
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT05408910
  13. Terminated

    Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes

    Reason given in the registry

    “Difficulties of inclusion in this rare pathology”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Mar 2025.

    Ended
    Jan 2025
    Phase
    Phase 4
    Run by
    University Hospital, Strasbourg, France
    Registry record
    NCT04381429
  14. Terminated

    Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

    Reason given in the registry

    “Difficulty enrolling”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Dec 2024.

    Ended
    Dec 2024
    Phase
    Phase 4
    Run by
    Hartford Hospital
    Registry record
    NCT05561764
  15. Terminated

    Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

    Reason given in the registry

    “Low recruitment, low interest from participant population”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Sept 2024.

    Ended
    Sept 2024
    Run by
    University of Missouri-Columbia
    Registry record
    NCT05392855
  16. Terminated

    A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting

    Reason given in the registry

    “Data”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Aug 2024.

    Ended
    Aug 2024
    Run by
    Hill-Rom
    Registry record
    NCT04017312
  17. Terminated

    Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

    Reason given in the registry

    “TSC recommended early termination due to lack of futility of the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 May 2024.

    Ended
    Apr 2024
    Phase
    Phase 2
    Run by
    Papworth Hospital NHS Foundation Trust
    Registry record
    NCT05101915
  18. Withdrawn

    Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

    Reason given in the registry

    “Time and resource deficiency at the Stockholm CF Center.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Mar 2024.

    Ended
    Dec 2025
    Run by
    Karolinska University Hospital
    Registry record
    NCT02605538
  19. Withdrawn

    A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

    Reason given in the registry

    “Pandemic, logistical, and recruitment challenges”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2023.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    Krystal Biotech, Inc.
    Registry record
    NCT05095246
  20. Withdrawn

    Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

    Reason given in the registry

    “No participants enrolled”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2023.

    Ended
    Dec 2023
    Run by
    Dartmouth-Hitchcock Medical Center
    Registry record
    NCT05229640
  21. Withdrawn

    Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

    Reason given in the registry

    “PI left the institution”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2020.

    Phase
    Phase 1
    Run by
    Joshua M Hare
    Registry record
    NCT03058068

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.